Statistik Asas
| LEI | 5493007V5QDIWECEYV79 |
| CIK | 1178711 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Paratek Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| October 2, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 5) RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. (Name of the Issuer) Paratek Pharmaceuticals, Inc. GPC WH Fund LP Novo Holdings A/S Resistance GP LLC Resistance TopCo L.P. Resistance Holdings, Inc. Resistance Intermediate, Inc. Resista |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
Exhibit 10.1 PARATEK PHARMACEUTICALS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee, FIRST SUPPLEMENTAL INDENTURE Dated as of September 21, 2023 to Indenture Dated as of April 23, 2018 4.75% Convertible Senior Subordinated Notes due 2024 FIRST SUPPLEMENTAL INDENTURE, dated as of September 21, 2023 (this “Supplemental Indenture”), between PARATEK PHARMACEUTICALS, INC., a Delawar |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc. EX-99.1 Exhibit 99.1 Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc. CAMBRIDGE, MASSACHUSETTS, Sept. 21, 2023 – Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceu |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
Form 25 |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2023 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Co |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
EIGHTH AMENDED & RESTATED CERTIFICATE OF INCORPORATION PARATEK PHARMACEUTICALS, INC. EX-3.1 Exhibit 3.1 EIGHTH AMENDED & RESTATED CERTIFICATE OF INCORPORATION OF PARATEK PHARMACEUTICALS, INC. FIRST: The name of the Company is Paratek Pharmaceuticals, Inc. SECOND: The address of the Company’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. THIRD: The purpose of the Company is to engage |
|
| September 21, 2023 |
SECOND AMENEDED & RESTATED PARATEK PHARMACEUTICALS, INC. As effective on September 21, 2023 EX-3.2 Exhibit 3.2 SECOND AMENEDED & RESTATED BY-LAWS OF PARATEK PHARMACEUTICALS, INC. As effective on September 21, 2023 SECOND AMENDED & RESTATED BY-LAWS OF PARATEK PHARMACEUTICALS, INC. PREAMBLE These By-Laws are subject to, and governed by, the General Corporation Law of the State of Delaware (the “DGCL”) and the certificate of incorporation of Paratek Pharmaceuticals, Inc., a Delaware corpora |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 21, 2023 As filed with the Securities and Exchange Commission on September 21, 2023 Registration No. |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 18, 2023 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Co |
|
| September 18, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 4) RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. (Name of the Issuer) Paratek Pharmaceuticals, Inc. GPC WH Fund LP Novo Holdings A/S Resistance GP LLC Resistance TopCo L.P. Resistance Holdings, Inc. Resistance Intermediate, Inc. Resista |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 12, 2023 |
DEFA14A 1 d456385ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 11, 2023 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Co |
|
| September 11, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 11, 2023 |
SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 3) RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. (Name of the Issuer) Paratek Pharmaceuticals, Inc. GPC WH Fund LP Novo Holdings A/S Resistance GP LLC Resistance TopCo L.P. Resistance Holdings, Inc. Resistance Intermediate, In |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| September 5, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated September 5, 2023 (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Paratek Pharmaceuticals, Inc., |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 2) RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. (Name of the Issuer) Paratek Pharmaceuticals, Inc. GPC WH Fund LP Novo Holdings A/S Resistance GP LLC Resistance TopCo L.P. Resistance Holdings, Inc. Resistance Intermediate, Inc. Resista |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2023 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PA |
|
| August 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| August 2, 2023 |
ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM August 2, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attention: Perry Hindin, Special Counsel Re: Paratek Pharmaceuticals, Inc. Amendment No. 1 to Schedule 13E-3 filed July 28, 2023 File |
|
| July 28, 2023 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 28, 2023 |
ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM July 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attention: Perry Hindin, Special Counsel Re: Paratek Pharmaceuticals, Inc. Schedule 13E-3 filed June 30, 2023 File No. 005-81821 Prelim |
|
| July 28, 2023 |
SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 1) RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. (Name of the Issuer) Paratek Pharmaceuticals, Inc. GPC WH Fund LP Novo Holdings A/S Resistance GP LLC Resistance TopCo L.P. Resistance Holdings, Inc. Resistance Intermediate, In |
|
| July 11, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Pursuant to §240. |
|
| July 11, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 6, 2023 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commissi |
|
| June 30, 2023 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 30, 2023 |
EX-99.(b)(i) Exhibit (b)(i) EXECUTION VERSION OAKTREE CAPITAL MANAGEMENT, L.P. 333 S. GRAND AVENUE, 28TH FLOOR LOS ANGELES, CA 90071 Highly Confidential June 6, 2023 Resistance Acquisition, Inc. c/o Gurnet Point Capital 55 Cambridge Parkway, Suite 401 Cambridge MA 02142 Attention: Adam Dilluvio Project Resistance Commitment Letter Ladies and Gentlemen: You have advised Oaktree Capital Management, |
|
| June 30, 2023 |
EX-99.(c)(iv) Exhibit (c)(iv) STRICTLY CONFIDENTIAL Pinto Illustrative Financial Analysis Selected Precedent Transactions Analysis – Transaction Metrics 1 Upfront TEV Contingent Value Total Value NTM Rev Consideration Premia Upfront / Announced Target Acquiror Indication ($mm) ($mm) ($mm) ($mm) Cash Equity 1 day 1 month NTM Rev. 02/15/2023 Emergent (Traveler's Vaccines) Bavarian Nordic Typhoid, Ch |
|
| June 30, 2023 |
Form of Subscription Agreement for Terminating Employees. EX-99.(d)(iv)(b) Exhibit (d)(iv)(b) SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is entered into as of June 6, 2023 by and among Resistance TopCo L.P., a Delaware limited partnership (“Topco LP”), Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual listed on the Schedule A attached hereto (“Subscriber”). Any capitalized term used herei |
|
| June 30, 2023 |
Form of Subscription Agreement for Continuing Employees (Standard). EX-99.(d)(iv)(c) Exhibit (d)(iv)(c) SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is entered into as of June 6, 2023 by and among Resistance TopCo L.P., a Delaware limited partnership (“Topco LP”), Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual listed on the Schedule A attached hereto (“Subscriber”). Any capitalized term used herei |
|
| June 30, 2023 |
EX-99.(c)(iii) Exhibit (c)(iii) |
|
| June 30, 2023 |
Form of Subscription Agreement for Former Employees. EX-99.(d)(iv)(a) Exhibit (d)(iv)(a) SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is entered into as of June 6, 2023 by and among Resistance TopCo L.P., a Delaware limited partnership (“Topco LP”), Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual listed on the Schedule A attached hereto (“Subscriber”). Any capitalized term used herei |
|
| June 30, 2023 |
EX-99.(d)(vi) Exhibit (d)(vi) June 6, 2023 Resistance Acquisition, Inc. c/o Gurnet Point Capital 55 Cambridge Parkway, Suite 401 Cambridge, MA 02142 Ladies and Gentlemen: This letter agreement (this “Agreement”) sets forth the commitment of GPC WH FUND LP, a Delaware limited partnership (the “Investor”), subject to the terms and conditions contained in this Agreement, to contribute or cause to be |
|
| June 30, 2023 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 13E-3 (Form Type) Paratek Pharmaceuticals, Inc. |
|
| June 30, 2023 |
EX-99.(d)(v) Exhibit (d)(v) EXECUTION VERSION LIMITED GUARANTEE THIS LIMITED GUARANTEE, dated as of June 6, 2023 (this “Limited Guarantee”), by GPC WH FUND LP, a Delaware limited partnership (the “Guarantor”), is in favor of Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Guaranteed Party”). 1. LIMITED GUARANTEE. To induce the Guaranteed Party to enter into that certain Agreement and P |
|
| June 30, 2023 |
SC 13E3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. (Name of the Issuer) Paratek Pharmaceuticals, Inc. GPC WH Fund LP Novo Holdings A/S Resistance GP LLC Resistance TopCo L.P. Resistance Holdings, Inc. Resistance Intermediate, Inc. Resistance Acquis |
|
| June 30, 2023 |
Form of Subscription Agreement for Continuing Employees (Put Option). EX-99.(d)(iv)(d) Exhibit (d)(iv)(d) SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is entered into as of June 6, 2023 by and among Resistance TopCo L.P., a Delaware limited partnership (“Topco LP”), Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual listed on the Schedule A attached hereto (“Subscriber”). Any capitalized term used herei |
|
| June 30, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Paratek Pharmaceuticals, Inc. |
|
| June 30, 2023 |
EX-99.(c)(ii) Exhibit (c)(ii) |
|
| June 27, 2023 |
Exhibit 99.1 NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital Intends to Withhold Its Votes Against All Three Board Members Up for Election at the Annual Meeting Citing the Board’s Failure to Hold Management Accountable for Years of Underperformance Plans to Carefully Scrutinize th |
|
| June 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Pursuant to §240. |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) D.C. SA |
|
| June 7, 2023 |
EX-10.1 Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•], 2023 (this “Agreement”), is entered into by and between Resistance Acquisition, Inc., a Delaware corporation (“Parent”), and [•], a [•] (“Rights Agent”). RECITALS WHEREAS, Parent, Resistance Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“M |
|
| June 7, 2023 |
Form of Voting Agreement to be entered into between Parent and the Management Stockholders. EX-10.2 Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 6, 2023 is entered into by and among [•], a [•] (“Stockholder”) and Resistance Acquisition, Inc., a Delaware corporation (“Parent”). WHEREAS, contemporaneously with the execution of this Agreement, Parent, Resistance Merger Sub, Inc., a Delaware corporation and wholly owned Subs |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commiss |
|
| June 7, 2023 |
EX-99.1 Exhibit 99.1 Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 on Achievement of a Commercial Milestone Total Transaction Consideration |
|
| June 7, 2023 |
DEFA14A 1 d407022ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other j |
|
| June 7, 2023 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among RESISTANCE ACQUISITION, INC. RESISTANCE MERGER SUB, INC. and PARATEK PHARMACEUTICALS, INC. Dated as of June 6, 2023 TABLE OF CONTENTS ARTICLE I THE MERGER 2 Section 1.1. The Merger 2 Section 1.2. Closing; Effective Time 2 Section 1.3. Effects of the Merger 2 Section 1.4. Certificate of Incorporation and Bylaws of the Surviving Corporation 2 Sec |
|
| June 6, 2023 |
DEFA14A 1 d512054ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| June 6, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Pursuant to §240. |
|
| June 6, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Pursuant to §240. |
|
| June 6, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Pursuant to §240. |
|
| May 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 26, 2023 |
and Proxy Statement Notice of Annual Meeting of Shareholders 2023 Date: July 6, 2023 75 Park Plaza 3 rd Floor Boston, MA 02116 617-807-66001 2023 Proxy Statement Letter to Our Shareholders Dear Fellow Shareholders, Paratek sustained its leadership position in the anti-infectives arena in 2022, as the company continued to grow sales and expand access to NUZYRA® (omadacycline) while advancing major opportunities, including studying our novel antibiotic as a potential treatment for patients suffering from the orphan disease non-tuberculous mycobacteria, or NTM, and delivering on key commitments in our unique public-private partnership with the Biomedical Advanced Research and Development Authority, or BARDA. |
|
| May 15, 2023 |
PARATEK PHARMACEUTICALS, INC. 75 Park Plaza Boston, MA 02116 PARATEK PHARMACEUTICALS, INC. 75 Park Plaza Boston, MA 02116 May 15, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Paratek Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-271780) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securitie |
|
| May 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 9, 2023 |
As filed with the Securities and Exchange Commission on May 9, 2023 S-3 1 prtk-sx3.htm S-3 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Paratek Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organiz |
|
| May 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Paratek Pharmaceuticals, Inc. |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 P |
|
| May 9, 2023 |
Exhibit 4.3 PARATEK PHARMACEUTICALS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of [ ], [ ] TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS. 1 1.2. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 5 1.3. RULES OF CONSTRUCTION. 5 ARTICLE 2. THE SECURITIES 6 2.1. ISSUABLE IN SERIES. 6 2.2. ESTABLISHMENT OF TERMS |
|
| May 9, 2023 |
Statement of Eligibility of Trustee under the Debt Indenture Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact n |
|
| March 30, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 PARATEK PHARMECEUTICALS, INC. |
|
| March 20, 2023 |
PRTK / Paratek Pharmaceuticals Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 3 Under the Securities Exchange Act of 1934 Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 699374302 (CUSIP Number) March 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| March 17, 2023 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 17, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0960223 (State or other jurisdiction of incorporation or organization) (IRS |
|
| March 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Paratek Pharmaceuticals, Inc. |
|
| March 16, 2023 |
Exhibit [●] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 16, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 16, 2023 |
Tenant: Paratek Pharmaceuticals Premises: 1000 First Avenue, Suite 400 LEASE THIS LEASE (this “Lease”) is entered into as of January 23, 2015, between ATLANTIC AMERICAN PROPERTIES TRUST, a Maryland real estate investment trust (“Landlord”), and PARATEK PHARMACEUTICALS LLC, a Delaware limited liability company (“Tenant”). |
|
| March 16, 2023 |
Exhibit 21.1 Paratek Pharmaceuticals, Inc. Subsidiaries Paratek Ireland Limited Paratek Pharma, LLC Paratek Royalty Corporation Paratek Royalty Corporation II Paratek Securities Corporation PRTK SPV1 LLC PRTK SPV2 LLC Transcept Pharma, Inc. |
|
| March 16, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 16, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact nam |
|
| March 14, 2023 |
EX-3.1 2 exhibit31.htm EX-3.1 EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF PARATEK PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE -i- ARTICLE I OFFICES .................................................................................................................... 1 Section 1. Registered Office ............................................................................... |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2023 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation or organ |
|
| February 15, 2023 |
PRTK / Paratek Pharmaceuticals Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 13, 2023 |
PRTK / Paratek Pharmaceuticals Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 20, 2023 |
SC 13G/A 1 nreo20230119sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par val |
|
| November 3, 2022 |
exhibit101 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Execution Copy COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between WARNER CHILCOTT COMPANY, INC. and PARATEK PHARMACEUTICALS, INC. July 2, 2007 -i- TABLE OF CONTENTS A |
|
| November 3, 2022 |
exhibit102 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PRODUCT AGREEMENT This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated July 28, 2017 and as amended by t |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-360 |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PA |
|
| July 7, 2022 |
PRTK / Paratek Pharmaceuticals Inc / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No.1 Under the Securities Exchange Act of 1934 Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 699374302 (CUSIP Number) July 5, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2022 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commissi |
|
| May 18, 2022 |
PRTK / Paratek Pharmaceuticals Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 699374302 (CUSIP Number) May 9, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 P |
|
| April 22, 2022 | ||
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 22, 2022 |
DEF 14A 1 prtk4025781-def14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confident |
|
| March 15, 2022 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 15, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0960223 (State or other jurisdiction of incorporation or organization) (IRS |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Paratek Pharmaceuticals, Inc. |
|
| March 14, 2022 |
Exhibit 10.40 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIFTH AMENDMENT TO THE AMENDED AND RESTATED MANUFACTURING AND SERVICES AGREEMENT This Fifth Amendment to the Amended and Restated Manufacturing and Services Agreement (the ?Fifth Amen |
|
| March 14, 2022 |
Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended Exhibit 10.6A PARATEK PHARMACEUTICALS, INC. 2017 INDUCEMENT PLAN, AS AMENDED ADOPTED: JUNE 15, 2017 AMENDED: OCTOBER 16, 2018 AMENDED: MARCH 9, 2022 1. GENERAL. (a)Eligible Award Recipients. Awards under the Plan may only be granted to an individual not previously an Employee or Director of the Company, or to an individual following a bona fide period of non-employment with the Company, as an indu |
|
| March 14, 2022 |
Non-Employee Director Compensation Policy. Exhibit 10.9 PARATEK PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the "Board") who is not also serving as an employee of Paratek Pharmaceuticals, Inc. (the "Company") or any of its subsidiaries (each such member, an "Eligible Director") will receive the compensation described in this Non-Employee Director Compensation Policy for his or her |
|
| March 14, 2022 |
Exhibit 10.45 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT AGREEMENT ? AMENDMENT NO.4 TO THE PRODUCT AGREEMENT DATED JULY 28, 2017 THIS FOURTH AMENDMENT AGREEMENT is dated November 17, 2021 (the ?Fourth Amendment Effective Date?) PA |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| March 14, 2022 |
Exhibit 21.1 Paratek Pharmaceuticals, Inc. Subsidiaries Paratek Ireland Limited Paratek Pharma, LLC Paratek Royalty Corporation Paratek Royalty Corporation II Paratek Securities Corporation PRTK SPV1 LLC PRTK SPV2 LLC Transcept Pharma, Inc. |
|
| March 11, 2022 |
PRTK / Paratek Pharmaceuticals Inc / DONDERO JAMES D - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. |
|
| March 11, 2022 |
EXHIBIT 99-1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0. |
|
| March 9, 2022 |
PRTK / Paratek Pharmaceuticals Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 699374302 (CUSIP Number) February 9, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMAC |
|
| November 8, 2021 |
Supply Agreement, dated July 14, 2021, between Paratek Pharmaceuticals, Inc. and CARBOGEN AMCIS AG. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version Supply Agreement Between Paratek Pharmaceuticals, Inc. and CARBOGEN AMCIS AG Date July 14, 2021 Table of Contents Article 1 Interpretation 1 1.1. Definitions 1 |
|
| November 8, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 4 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJE |
|
| November 8, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 5 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJE |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 23, 2021 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation or o |
|
| September 27, 2021 |
Exhibit 99.1 Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA? (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax - Additional ~$19M Funding for Expanded Anthrax PEP Development Program - BARDA Contract Now Valued at Up to ~$304M - Development Milestones Specified for Future Procurements BOSTON, Se |
|
| August 9, 2021 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation. Exhibit 3.4 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals, Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the" DGCL"), DOES HEREBY CERTIFY: FIRST: The name of the Corporation is Paratek Pharmaceut |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMACEUTIC |
|
| July 14, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2021 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation or organi |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2021 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commissi |
|
| June 14, 2021 |
Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors Exhibit 99.1 Paratek Appoints Minnie Baylor-Henry to Company?s Board of Directors BOSTON, June 14, 2021 - Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the |
|
| May 17, 2021 |
Up to $50,000,000 Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-238150 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2020) Up to $50,000,000 Common Stock We have entered into an At the Market Sales Agreement, or sales agreement, with BTIG, LLC, or BTIG, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with t |
|
| May 17, 2021 |
Exhibit 1.1 Paratek Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) AT THE MARKET SALES AGREEMENT May 17, 2021 BTIG, LLC 825 Third Avenue, 6th Floor New York, New York 10022 Ladies and Gentlemen: Paratek Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with BTIG, LLC (the ?Agent?) as follows: 1.Issuance and Sale of S |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMACEUTI |
|
| April 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| April 23, 2021 |
- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 23, 2021 |
begin 644 prtkcourtesy-pdf.pdf M)5!$1BTQ+C<-"B6AL\77#0HQ(# @;V)J#0H\/"]086=E7!E+U!A9V5S/CX- M"F5N9&]B:@T*,R P(&]B:@T*/#PO0W)E871I;VY$871E*$0Z,C R,3 T,C0P M,#0P,#%L@," P M(#4Y-" W-S1=+TUE9&EA0F]X6R P(# @-3DT(#?V&RHQ9N8G6W11W/]L+RZ?7QOWCQ]^L]7\^[Y]OG^X?[Q^;OK?RZX M;'VLYOK]\NJOGYYN;LWGSZ8/ST^OOV:%[?WS\O@S=]Y]O'VZCI^/[^ MZ5?>(V/IC&-2QOA9&:=0;(ZU*>,;%PJ^/'X3;]TO7Q>>"FU:$J)YNE^^9MY M7#Z#(K?%Q!!LK0[*@%9S |
|
| April 13, 2021 |
PRE 14A 1 prtk3887701-pre14a.htm PRELIMINARY PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confiden |
|
| April 13, 2021 |
- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 30, 2021 |
S-8 1 prtk-s8.htm S-8 Registration No. 333- As filed with the Securities and Exchange Commission on March 30, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0960223 (State or other jurisdiction of incorporation |
|
| March 29, 2021 |
Exhibit 21.1 Paratek Pharmaceuticals, Inc. Subsidiaries Paratek Ireland Limited Paratek Pharma, LLC Paratek Royalty Corporation Paratek Royalty Corporation II Paratek Securities Corporation Paratek UK Limited PRTK SPV1 LLC PRTK SPV2 LLC Transcept Pharma, Inc. |
|
| March 29, 2021 |
Non-Employee Director Compensation Policy. Exhibit 10.9 PARATEK PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the "Board") who is not also serving as an employee of Paratek Pharmaceuticals, Inc. (the "Company") or any of its subsidiaries (each such member, an "Eligible Director") will receive the compensation described in this Non-Employee Director Compensation Policy for his or her |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2020 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| March 29, 2021 |
Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [Execution Copy] TUFTS UNIVERSITY LICENSE AGREEMENT This Agreement is made and entered into as of February 1, 1997 ("the Effective Date"), by and between Paratek Pharmaceuticals |
|
| March 29, 2021 |
Exhibit 10.50 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 4 2. AMENDMENT/MODIFICATION NO. P0001 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ.NO. S |
|
| February 24, 2021 |
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. |
|
| February 24, 2021 |
Exhibit 99.1 Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million - NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 - NUZYRA Expansion into the Primary Care Setting in 2021 - Paratek Expects Full Year 2021 Total Revenue Between $166 and |
|
| February 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 24, 2021 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Com |
|
| February 12, 2021 |
EXHIBIT 99-1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0. |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. |
|
| February 9, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| January 4, 2021 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO THE MANUFACTURING AND SERVICES AGREEMENT This First Amendment to the Manufacturing and Services Agreement (the “First Amendment”) is made as of September 4, 2020 (the “Effe |
|
| January 4, 2021 |
Exhibit 10.3 EXECUTION VERSION CONTRIBUTION AND SERVICING AGREEMENT dated as of December 31, 2020 by and between PARATEK PHARMACEUTICALS, INC., as Contributor, and PRTK SPV2 LLC, as Company ACTIVE/105323943.11 Table of Contents Page Article I DEFINITIONS 1 Section 1.01 Definitions1 Section 1.02 Rules of Construction4 Article II ASSIGNMENT OF THE TRANSFERRED ASSETS 5 Section 2.01 Assignment of Tran |
|
| January 4, 2021 |
Exhibit 10.1 EXECUTION VERSION LOAN AGREEMENT dated as of December 31, 2020 by and between R-BRIDGE HEALTHCARE CAYMAN AIV, L.P., as Lender, and PRTK SPV2 LLC, as Borrower ACTIVE/105942580.15 Table of Contents Page Article I CERTAIN DEFINITIONS 1 Section 1.01 Definitions1 Section 1.02 Rules of Construction23 Article II THE LOAN; DISBURSEMENT; CERTAIN FEES 24 Section 2.01 The Loan24 Section 2.02 Dis |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 31, 2020 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Com |
|
| January 4, 2021 |
Exhibit 10.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FOURTH AMENDMENT TO THE AMENDED AND RESTATED MANUFACTURING AND SERVICES AGREEMENT This Fourth Amendment to the Amended and Restated Manufacturing and Services Agreement (the “Fourth Amendment |
|
| January 4, 2021 |
Exhibit 10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. DocuSign Envelope ID: 1D5A3E34-CCC5-466C-80BD-0FCCC34267BF THIRD AMENDMENT TO THE AMENDED AND RESTATED MANUFACTURING AND SERVICES AGREEMENT This Third Amendment to the Amended and Restated Ma |
|
| January 4, 2021 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDMENT OF MANUFACTURING AND SERVICES AGREEMENT THIS SECOND AMENDMENT (the “Second Amendment”) is made as of December 18, 2020 (the “Effective Date”) by and between Paratek Pharmace |
|
| January 4, 2021 |
Exhibit 10.9 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT OF MANUFACTURING AND SERVICES AGREEMENT THIS FIRST AMENDMENT (the “Amendment”) is made as of the 01 day of June, 2019 (the “Effective Date”) by and between Paratek Pharmaceuti |
|
| January 4, 2021 |
Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDMENT TO THE MANUFACTURING AND SERVICES AGREEMENT This Second Amendment to the Manufacturing and Services Agreement (the “Second Amendment”) is made as of January 1, 2021 (the “Eff |
|
| January 4, 2021 |
Exhibit 10.2 EXECUTION VERSION REVENUE INTEREST PURCHASE AGREEMENT dated as of December 31, 2020 by and between PARATEK PHARMACEUTICALS, INC., as Seller, and PRTK SPV2 LLC, as Company Table of Contents Page Article I DEFINITIONS 1 Section 1.01 Definitions1 Section 1.02 Rules of Construction9 Article II PURCHASE AND SALE OF THE PURCHASED REVENUE INTEREST 10 Section 2.01 Purchase and Sale10 Section |
|
| January 4, 2021 |
Exhibit 10.11 AMENDMENT AGREEMENT – AMENDMENT NO. 2 TO THE PRODUCT AGREEMENT DATED JULY 28, 2017 THIS SECOND AMENDMENT AGREEMENT is dated June 1, 2019 (the “Amendment Effective Date”) PARTIES 1. PATHEON UK LIMITED (Registration No. 3764421) incorporated and registered in England whose registered office is at Kingfisher Drive, Covingham, Swindon, Wiltshire, SN3 5BZ, England (“Patheon”); and 2. PARA |
|
| January 4, 2021 |
Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT AGREEMENT ‑ AMENDMENT NO.3 TO THE PRODUCT AGREEMENT DATED JULY 28, 2017 THIS THIRD AMENDMENT AGREEMENT is dated July 1, 2020 (the “Third Amendment Effective Date”) PARTIES 1. PATHE |
|
| January 4, 2021 |
Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDMENT TO THE AMENDED AND RESTATED MANUFACTURING AND SERVICES AGREEMENT This Second Amendment to the Amended and Restated Manufacturing and Services Agreement (the “Second Amendment |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMAC |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMACEUTIC |
|
| August 10, 2020 |
HTML Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of August 5, 2020 and is entered into by and among (a) (i) PARATEK PHARMACEUTICALS, INC., a Delaware corporation (“Inc.”) (ii) PARATEK PHARMA, LLC, A Delaware limited liability company (“LLC”), and (iii) each o |
|
| August 10, 2020 |
Warrant Agreement, dated as of August 5, 2020 issued to Hercules Capital, Inc. HTML Exhibit 4.9 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) RE |
|
| July 7, 2020 |
PARATEK PHARMACEUTICALS, INC. 75 Park Plaza Boston, Massachusetts 02116 (617) 807-6600 July 7, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 RE: Paratek Pharmaceuticals, Inc. Registration Statement on Form S-3, as amended (File No. 333-238150) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 prom |
|
| June 19, 2020 |
CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW. |
|
| June 19, 2020 |
S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 19, 2020 Registration No. |
|
| June 12, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2020 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commiss |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMACEUTI |
|
| May 11, 2020 |
Non-Employee Director Compensation Policy. EX-10.1 2 prtk-ex101348.htm EX-10.1 Exhibit 10.1 PARATEK PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the "Board") who is not also serving as an employee of Paratek Pharmaceuticals, Inc. (the "Company") or any of its subsidiaries (each such member, an "Eligible Director") will receive the compensation described in this Non-Employee Director |
|
| May 11, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on May 11, 2020 Registration No. |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 24, 2020 |
DEF 14A 1 prtk-def14a20200610.htm DEF 14A e UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| March 11, 2020 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 11, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0960223 (State or other jurisdiction of incorporation or organization) (IRS |
|
| March 10, 2020 |
Exhibit 10.36 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. PARATEK PHARMACEUTICALS paratekpharma.com 75 Park Plaza Boston, MA 02116 617.807.6600 617.275.0039 fax December 19, 2019 Zai Lab (Shanghai Co., Ltd.) 1043 Halei Road, Building 8, Suite 502 Z |
|
| March 10, 2020 |
Exhibit 10.35 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) RATING PAGE OF PAGES 1 3 2. CONTRACT (Proc. Inst. Ident) NO. 75A50120C00001 3. EFFECTIVE DATE See Block 20C 4. REQUIS |
|
| March 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| March 10, 2020 |
Exhibit 21.1 Paratek Pharmaceuticals, Inc. Subsidiaries Paratek Bermuda Ltd. Paratek Ireland Limited Paratek Pharma, LLC Paratek Royalty Corporation Paratek Securities Corporation Paratek UK Limited Transcept Pharma, Inc. |
|
| March 10, 2020 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Paratek Pharmaceuticals, Inc. (“Paratek,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.001 par value per share. DESCRIPTION OF CAPITAL STOCK |
|
| February 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2020 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Com |
|
| February 25, 2020 |
Fourth Quarter & Full Year 2019 Financial Results & Corporate Update February 25, 2020 Paratek Pharmaceuticals, Inc. |
|
| February 25, 2020 |
EX-99.1 2 prtk-ex9917.htm EX-99.1 Exhibit 99.1 Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million - Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million - Paratek Now Anticipates its Cash Runway Will Extend Through the End of 2 |
|
| February 14, 2020 |
PRTK / Paratek Pharmaceuticals, Inc. / HIGHLAND CAPITAL MANAGEMENT LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 99-1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Paratek Pharmaceuticals, Inc., a Delaware corporation, and fu |
|
| February 14, 2020 |
PRTK / Paratek Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 11, 2020 |
PRTK / Paratek Pharmaceuticals, Inc. / UBS Group AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| December 18, 2019 |
8-K 1 prtk-8k20191218.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 18, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other juris |
|
| December 18, 2019 |
Paratek Awarded BARDA Project BioShield Contract for NUZYRA® Paratek Awarded BARDA Project BioShield Contract for NUZYRA® - Total award valued at up to $285 million - Paratek to host a conference call today, December 18, 2019 at 5:30 p. |
|
| December 9, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. / Baupost Group LLC/MA - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 699374302 (CUSIP Number) November 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| November 12, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 prtk-10q20190930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file |
|
| August 6, 2019 |
EX-10.3 3 prtk-ex103152.htm EX-10.3 Exhibit 10.3 PARATEK PHARMACEUTICALS paratekpharma.com 75 Park Plaza Boston, MA 02116 617.807.6600 617.275.0039 fax June 25, 2019 Evan Loh, M.D. Re:Amended and Restated Employment Agreement Dear Evan: On behalf of the Board of Directors (the “Board”) of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”), I am pleased to offer you continued employment und |
|
| August 6, 2019 |
EX-10.4 4 prtk-ex104153.htm EX-10.4 Exhibit 10.4 PARATEK PHARMACEUTICALS paratekpharma.com 75 Park Plaza Boston, MA 02116 617.807.6600 617.275.0039 fax June 25, 2019 Adam Woodrow Re: Amended and Restated Employment Agreement Dear Adam: On behalf of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”), I am pleased to offer you continued employment under the terms of this Amended and Restated |
|
| August 6, 2019 |
Exhibit 10.2 PARATEK PHARMACEUTICALS paratekpharma.com 75 Park Plaza Boston, MA 02116 617.807.6600 617.275.0039 fax June 25, 2019 Michael F. Bigham Re:Amended and Restated Employment Agreement Dear Michael: On behalf of the Board of Directors (the “Board”) of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”), I am pleased to offer you continued employment under the terms of this Amended a |
|
| August 6, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36066 PARATEK PHARMACEUTIC |
|
| July 2, 2019 |
Up to $50,000,000 Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-221843 PROSPECTUS SUPPLEMENT (To Prospectus dated December 8, 2017) Up to $50,000,000 Common Stock We have entered into an At the Market Sales Agreement, or sales agreement, with Jeffries LLC and BTIG, LLC, each a sales agent and, collectively, the sales agents, relating to shares of our common stock offered by this p |
|
| July 2, 2019 |
8-K 1 prtk-8k20190627.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdict |
|
| July 2, 2019 |
EX-10.1 4 prtk-ex1017.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and dated as of June 27, 2019 and is entered into by and among (a) (i) PARATEK PHARMACEUTICALS, INC., a Delaware corporation (“Inc.”), (ii) PARATEK PHARMA, LLC, a Delaware limited liability company (“LLC”), and (iii) each of its Qualified Sub |
|
| July 2, 2019 |
EX-1.1 2 prtk-ex1150.htm EX-1.1 Exhibit 1.1 Paratek Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) AT THE MARKET SALES AGREEMENT July 2, 2019 Jefferies LLC 520 Madison Avenue New York, New York 10022 BTIG, LLC 825 Third Avenue, 6th Floor New York, New York 10022 Ladies and Gentlemen: Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agre |
|
| June 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commiss |
|
| June 26, 2019 |
EX-99.1 2 prtk-ex9916.htm EX-99.1 Exhibit 99.1 Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman -Adam Woodrow Promoted to President & Retains Chief Commercial Officer Position -Randy Brenner Promoted to Chief Development & Regulatory Officer Boston, June 25, 2019 – Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharm |
|
| June 12, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commiss |
|
| May 8, 2019 |
10-Q 1 prtk-10q20190331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file numb |
|
| May 8, 2019 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT AGREEMENT – AMENDMENT NO. 1 TO THE PRODUCT AGREEMENT DATED 28 JULY 2017 THIS AMENDMENT AGREEMENT is dated 01 JANUARY 2019 (the “Amendment Effective Date”) PARTIES 1. PATHEON UK LIMI |
|
| May 8, 2019 |
Exhibit 10.2 EXECUTION LOAN AGREEMENT Dated as of February 26, 2019 Between HEALTHCARE ROYALTY PARTNERS III, L.P., as Lender, and PARATEK ROYALTY CORPORATION, as Borrower TABLE OF CONTENTS Page ARTICLE I. CERTAIN DEFINITIONS SECTION 1.01 DEFINITIONS 1 SECTION 1.02 RULES OF CONSTRUCTION 19 ARTICLE II. THE LOAN; DISBURSEMENT; CERTAIN FEES SECTION 2.01 THE LOAN 21 SECTION 2.02 DISBURSEMENT AND BORROW |
|
| April 26, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2019 |
DEF 14A 1 prtk-def14a20190612.htm DEF 14A e SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Stat |
|
| March 18, 2019 |
Consulting Agreement dated March 15, 2019 between the Company and Douglas Pagán. EX-10.1 2 prtk-ex1017.htm EX-10.1 Exhibit 10.1 PARATEK PHARMACEUTICALS paratekpharma.com 75 Park Plaza Boston, MA 02116 617.807.6600 617.275.0039 fax March 15, 2019 By Hand Delivery Douglas Pagán (Hand Delivery) Dear Doug: As we have discussed, your employment with Paratek Pharmaceuticals, Inc. (the “Company”) will terminate, effective as of April 5, 2019 (the “Separation Date”). The purpose of th |
|
| March 18, 2019 |
Financial Statements and Exhibits 8-K 1 prtk-8k20190318.htm 8-K (CFO RESIGNATION) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State |
|
| March 18, 2019 |
Paratek Pharmaceuticals Announces Management Change EX-99.1 3 prtk-ex9916.htm EX-99.1 Exhibit 99.1 Paratek Pharmaceuticals Announces Management Change BOSTON, March 18, 2019 - Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that Douglas Pagán, Chief Financial Officer, has resigned, effective April 5, 2019, to join |
|
| March 6, 2019 |
Registration No. 333- As filed with the Securities and Exchange Commission on March 6, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0960223 (State or other jurisdiction of incorporation or organization) (IRS |
|
| March 6, 2019 |
Exhibit 21.1 Paratek Pharmaceuticals, Inc. Subsidiaries Paratek Bermuda Ltd. Paratek Ireland Limited Paratek Pharma, LLC Paratek Royalty Corporation Paratek Securities Corporation Paratek UK Limited Transcept Pharma, Inc. |
|
| March 6, 2019 |
cB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-36066 PARATEK PHARMACEUTICALS, INC. (Exact name of registrant |
|
| March 6, 2019 |
EX-10.33 2 prtk-ex1033734.htm EX-10.33 Exhibit 10.33 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIRST AMENDMENT OF AMENDED AND RESTATED MANUFACTURING AND SERVICES AGREEMENT THIS FIRST AMENDMENT OF AMENDED AND RESTATED MANUFACTURING AND SERVIC |
|
| March 6, 2019 |
EX-10.35 3 prtk-ex1035735.htm EX-10.35 Exhibit 10.35 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Execution Version FIRST AMENDMENT OF OUTSOURCING SERVICES AGREEMENT THIS FIRST AMENDMENT OF OUTSOURCING SERVICES AGREEMENT (the “Amendment”) is ma |
|
| February 27, 2019 |
EX-99.1 2 prtk-ex99115.htm EX-99.1 Exhibit 99.1 Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI - - New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA - - Company Executes SEYSARA™ Royalty-Backed Loan to Receive $32.5 Million - BO |
|
| February 27, 2019 |
Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update February 27, 2019 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. |
|
| February 27, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Com |
|
| February 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Com |
|
| February 15, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. / UBS Group AG - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Paratek Pharmaceuticals Inc (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 14, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. / HIGHLAND CAPITAL MANAGEMENT LP - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Paratek Pharmaceuticals, Inc. |
|
| February 14, 2019 |
EX-99.1 2 d597251dex991.htm EX-99.1 EXHIBIT 99-1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Paratek Pharmaceuticals, Inc., a |
|
| February 14, 2019 |
PRTK / Paratek Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2019 |
SC 13G/A 1 p19-0369sc13ga.htm PARATEK PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Paratek Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 699374302 (CUSIP Number) December 31, 2018 (Date of event which requires filing of this |
|
| January 4, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2019 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Commi |
|
| January 4, 2019 |
Paratek Business Overview & Financial Update January 2019 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. |
|
| December 3, 2018 |
EX-99.1 2 prtk-ex9916.htm EX-99.1 Exhibit 99.1 Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRATM Patent Protection Exclusivity Until at Least October 2030 BOSTON, December 3, 2018 - Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, toda |
|
| December 3, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 3, 2018 Date of Report (Date of earliest event reported) PARATEK PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36066 33-0960223 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2018 |
PRTK / Paratek Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
